Peptides, Medtech, and the Obesity Treatment Market

18 months ago, weight-loss peptides looked like they might fundamentally reshape healthcare demand patterns overnight. Investors treated semaglutide and tirzepatide as existential threats to multiple device categories, from cardiovascular technologies to orthopedics, diabetes management, and surgical interventions. Today, the latest data suggests the obesity treatment market is evolving in a more complicated way.

The original disruption thesis was directionally understandable. Prescription growth has been extraordinary. But broad assumptions about collapsing device demand have not held up, at least not yet.

The Numbers Behind the Shift

Use of GLP-1 therapies among overweight or obese adults surged 587% between 2019 and 2024.

As of 2025, an estimated 13% of U.S. adults are using these therapies specifically for weight loss, compared with roughly 6% in early 2024.

That kind of adoption curve is difficult to ignore.

But has it materially changed obesity prevalence?

Yes, though not dramatically.

U.S. obesity rates peaked at approximately 40% in 2022. By 2025, that figure had declined to 37%, representing about 7.6 million fewer obese adults.

That sounds meaningful, but context matters. A 37% obesity rate essentially returns the U.S. to pre-pandemic levels rather than signaling a structural reversal of the broader obesity burden.

Diabetes prevalence tells a similarly sobering story. In 2025, 13.8% of U.S. adults were diagnosed with diabetes, compared with 10.6% roughly a decade earlier.

So while these therapies are having an effect, the underlying disease burden remains substantial.

At a glance:

• 587%+ growth in GLP-1 prescriptions (2019–2024)
• 12.4% of U.S. adults currently using GLP-1s for weight loss
• ~3% decline in obesity prevalence from 2022 to 2025
• 90% to 95% of severely obese patients still receiving no obesity treatment

Where Medtech Has Actually Felt the Impact

Most major medtech sectors have remained resilient.

The most obvious exception is bariatric surgery.

A 2025 JAMA Surgery analysis reported a 46% drop in bariatric procedures among eligible patients between 2022 and 2025. More recently, data presented at the 2026 ASMBS annual meeting showed bariatric and metabolic procedure volumes fell below 200,000 in 2024 for the first time since 2020, marking a 20% year-over-year decline.

This is real disruption.

Even so, the picture inside bariatrics is not entirely one-directional. Gastric bypass procedures have increased, suggesting some patients who initially pursued pharmacologic treatment may be returning to surgery when drug-based outcomes prove insufficient.

Outside bariatrics, the feared collapse in demand has not emerged. Cardiovascular technologies, diabetes management tools, and surgical robotics continue to attract capital and strategic interest.

Drug-Based Obesity Treatment Depends on Adherence

The central issue is not efficacy. It is persistence.

These therapies only meaningfully alter long-term disease trajectories if patients stay on them.

That is not what real-world data shows.

Among patients who initiated Wegovy or Zepbound in early 2024, only 63% remained on therapy after one year. Wegovy retention falls to just 14% after three years. Published discontinuation rates range from 36% to 81%.

Clinical trial performance also diverges sharply from real-world outcomes.

In controlled trials, patients lost 15% to 21% of body weight.

Outside trial settings:

• Semaglutide users lost 7.7% after one year
• Tirzepatide users lost 12.4%

The therapies work. But not as consistently, and not for as long, as headline trial data might suggest.

Cost remains a major obstacle.

Approximately 14% of patients discontinue because they cannot afford treatment. Coverage remains limited, with fewer than 20% of firms with 200+ workers covering GLP-1s for weight loss. Medicaid support is shrinking, and Medicare still cannot cover these drugs solely for obesity treatment.

Side effects likely compound the issue. In clinical trials, 30% to 40% of semaglutide users reported nausea, while roughly 20% experienced vomiting. Real-world discontinuation due to side effects has landed in the 10% to 15% range across studies.

Another factor may be patient selection. A notable portion of prescriptions have gone to adults with BMIs below 30, where indications are less clear, expected benefit is smaller, and motivation to remain on therapy may be weaker.

The Cardiovascular Question

One of the most important strategic questions is whether widespread GLP-1 adoption eventually reduces cardiovascular device demand.

The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in obese patients with established cardiovascular disease. That result helped drive FDA approval of Wegovy for cardiovascular risk reduction in 2024.

But continuity matters.

A WashU Medicine study involving more than 300,000 veterans found that patients who maintained GLP-1 therapy for three years saw an 18% reduction in cardiovascular risk.

Those who discontinued before 18 months saw no meaningful reduction versus non-users.

A six-month interruption erased much of the benefit. A two-year break increased cardiovascular risk by 22% relative to continuous therapy.

Weight regain followed a similar pattern, with patients regaining roughly 0.8 kg per month after stopping, often returning to baseline within 18 months.

That creates an unexpected dynamic: intermittent therapy may sustain rather than suppress demand for certain medtech devices.

Final Weigh-In on GLP-1s and the Obesity Treatment Market

The disruption narrative was not entirely wrong. It was simply ahead of the evidence.

Bariatric surgery is clearly under pressure. Other sectors that investors expected to suffer, including cardiovascular, orthopedics, and diabetes technologies, have not seen equivalent demand destruction.

For now, the bigger opportunity within the obesity treatment market may still be the vast untreated population, not the subset actively cycling through GLP-1 therapy.

The drugs are legitimate. Their long-term impact on most of medtech remains a slower-moving story.